Cargando…

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?

Detalles Bibliográficos
Autores principales:	Dutt, Tina, Simcox, David, Downey, Colin, McLenaghan, Daniella, King, Charlotte, Gautam, Manish, Lane, Steven, Burhan, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397804/ https://www.ncbi.nlm.nih.gov/pubmed/32510975 http://dx.doi.org/10.1164/rccm.202005-1654LE

Ejemplares similares

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis
por: Mehta, Puja, et al.
Publicado: (2021)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Renal function in the ICU: always look both ways before initiating venous thromboprophylaxis
por: Baptista, João Pedro, et al.
Publicado: (2023)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey
por: Ferrandis, Raquel, et al.
Publicado: (2021)

Tackling missed opportunities for vaccination in a new era of immunisation
por: Nnaji, Chukwudi A, et al.
Publicado: (2021)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017)

Just Missing the Mark: Discharging High-risk Atrial Fibrillation / Flutter without Thromboprophylaxis
por: Thompson, Linda B., et al.
Publicado: (2018)

Miss Anna Williams
por: Barter, J.
Publicado: (1888)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Pneumococcal colonisation is an asymptomatic event in healthy adults using an experimental human colonisation model
por: Trimble, Ashleigh, et al.
Publicado: (2020)

Thirteen-Valent Pneumococcal Conjugate Vaccine–Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung
por: Mitsi, Elena, et al.
Publicado: (2021)

Case reports describing treatments in the emergency medicine literature: missing and misleading information
por: Richason, Tiffany P, et al.
Publicado: (2009)

Missing PPI prescriptions while overprescribing?
por: Schubert, Ingrid, et al.
Publicado: (2023)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

This Article Corrects: “Just Missing the Mark: Discharging High-risk Atrial Fibrillation/Flutter without Thromboprophylaxis”
por: Thompson, Linda B., et al.
Publicado: (2019)

VERRUCOUS HEMANGIOMA OR ANGIOKERATOMA? A MISSED DIAGNOSIS
por: Pavithra, S, et al.
Publicado: (2011)

Comment on: Insulinoma in tuberous sclerosis: an entity not to be missed
por: Gadelkareem, Rabea A.
Publicado: (2021)

Intracranial pressure pulse morphology: the missing link?
por: Brasil, Sérgio
Publicado: (2022)

Deep vein thrombosis and thromboprophylaxis in arthroscopic anterior cruciate ligament reconstruction
por: Adala, Raviraj, et al.
Publicado: (2011)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Intraperitoneal Injection of Anti-Sera
por: King, H. H.
Publicado: (1924)

Another chemolithotrophic metabolism missing in nature: sulfur comproportionation
por: Amend, Jan P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbff408gil2gum00u45rj0641u